Polyclonal Antibodies Market Size is Valued at USD 2.74 Bn by 2034, Driven by a 5.04% CAGR

According to Towards Healthcare research, the global polyclonal antibodies market size is calculated at USD 1.76 billion in 2025 and is expected to reach around USD 2.74 billion by 2034, growing at a CAGR of 5.04% for the forecasted period.

/EIN News/ -- Ottawa, April 28, 2025 (GLOBE NEWSWIRE) -- The global polyclonal antibodies market size was valued at USD 1.68 billion in 2024 and is predicted to hit around USD 2.74 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research.

The polyclonal antibodies market is expanding due to the rising prevalence of chronic disorders and advancements in diagnostics. North America led the global market owing to state-of-the-art R&D facilities and the presence of key players.

Get All the Details in Our Solutions – Request a Brochure: https://www.towardshealthcare.com/download-brochure/5388

Market Overview

Polyclonal antibodies are a complex mixture of antibodies produced from different types of plasma B cells. Each antibody recognizes different epitopes of the same antigen. The polyclonal antibody extraction process is inexpensive and isolates large quantities of antibodies in a single extraction. These antibodies bind to an antigen and stimulate the body’s immune system to destroy that antigen. They are used in lab tests to diagnose diseases, study disease progression, and treat certain disorders.

Several factors govern the market growth, including the rising prevalence of chronic disorders and growing research. The increasing investments in R&D activities also boost the market. Technological advancements have led to the development of innovative extraction techniques. The burgeoning biopharmaceutical sector increases the development of novel antibody drugs. The growing use of laboratory diagnostic tests also potentiates the demand for polyclonal antibodies.

Polyclonal Antibodies Market Trends

• Rising Prevalence of Chronic Disorders: The rising prevalence of chronic disorders potentiates the demand for polyclonal antibodies, which are used to diagnose and treat such disorders. They are also used to treat some medication overdoses, snake venoms, and blood conditions.
• Advancements in Diagnostics: The rising need for early disease diagnosis leads to advancements in diagnostics. Immunodiagnostics, such as ELISA and immunohistochemistry, use polyclonal antibodies to detect infectious diseases and cancer.
• Growing Research & Development Activities: The increasing chronic disorder cases necessitates researchers to develop novel drugs and medical devices. This requires a detailed understanding of disease progression. Research antibodies enable researchers to understand how diseases affect human bodies.
  

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Limitations & Challenges in the Polyclonal Antibodies Market

• Lack of Specificity: Polyclonal antibodies are extracted from a natural source. Hence, they aren’t consistent, leading to batch-to-batch variability. This leads to a lack of specificity, restricting their usage.
• Cross-Reactivity: Polyclonal antibodies have a high chance of cross-reactivity due to recognition of multiple epitopes. This can cause issues when using them in testing or research, leading to false positives.

Virtual Immunization: A Computational Approach for Development

Artificial intelligence (AI) and other in silico approaches are leveraged to revolutionize polyclonal antibody discovery and development. These techniques can be used to select, screen, and optimize antibody sequences. This enables the rational design of antibody characteristics, such as binding sites and kinetics. Such virtual modifications may help researchers to develop antibodies with enhanced efficacy. The technique may reduce the dependence on expensive trial-and-error experimental methods. Moreover, advanced computational methods can assist in mapping the polyclonal responses within individuals, guiding the selection and optimization of antibody mixtures for therapeutic or diagnostic applications.

Regional Analysis

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Presence of Key Players Dominated North America

North America dominated the global polyclonal antibodies market in 2023. The rising prevalence of chronic disorders and the increasing adoption of advanced technologies drive the market. The availability of state-of-the-art research and development facilities leads to the development of novel antibody-based drugs. The presence of key players, such as Thermo Fisher Scientific, Pfizer, and Rapid Novor, holds the major share of the market in North America. Favorable government policies and regulatory frameworks enable pharma and biotech companies to launch novel products.

• United States: The Food and Drug Administration (FDA) regulates the approval of antibody-based drugs in the U.S. In 2023, 12 antibody-based drugs were approved.
• Canada: In September 2024, UBC researchers at Canada’s Immuno-Engineering & Biomanufacturing Hub (CIEBH) received funding of more than $31.4 million for three projects for the development of immune-based therapeutics, like mRNA vaccines, antibody treatments, and cell & gene therapies, in British Columbia for Canadians.

Asia-Pacific is anticipated to grow at the fastest rate in the polyclonal antibodies market during the forecast period. The increasing geriatric population leads to rising chronic disorders. The growing research and development activities and demand for innovative therapeutics augment the market. The increasing number of pharma and biotech startups and the rapidly expanding biopharmaceutical sector boost the market. Favorable government support, as well as increasing investments and collaborations, also contribute to market growth.

• China: China has emerged as a major supplier of polyclonal antibodies globally. There are around 112 polyclonal antibody suppliers in China. Wuhan Elabscience Biotechnology Co., Ltd., Fapon International Ltd., and Wuhan ServiceBio Technology Co., Ltd. account for 77% of the total supply of polyclonal antibodies in China.
• India: In 2025, 481 polyclonal antibody tenders were published in India. The Indian government’s “Make in India” initiative encourages local researchers and developers to extract and manufacture polyclonal antibodies in India

Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes—schedule a call today: https://www.towardshealthcare.com/schedule-meeting

Segmental Outlook

Product Insights

The secondary antibodies segment held a dominant presence in the polyclonal antibodies market in 2024. Secondary antibodies bind to the primary antibody, which in turn binds to antigens. They are widely used for the detection, sorting, or purification of target antigens. The demand for secondary antibodies is high, as they are easy to manufacture and cost-effective. Manufacturers can supply ready-to-use secondary antibodies that are appropriate for all applications. The increasing use of ELISA and Western blotting promotes the need for secondary antibodies as they are chemiluminescent, colorimetric, or fluorescence-based, boosting the segment’s growth.

The primary antibodies segment is expected to grow at the fastest rate in the market during the forecast period. Primary antibodies are essential components as they directly bind to the antigens. They are highly specific and sensitive to detect even minute changes in antigens. They are widely used for detecting and analyzing the presence of biomarkers in several disorders, such as Alzheimer’s disease, diabetes, cancer, and Parkinson’s disease, both quantitatively and qualitatively.

Application Insights

The diagnostics segment held the largest share of the polyclonal antibodies market in 2024. Polyclonal antibodies are vital for diagnosing disease conditions. Favorable government policies for early disease detection augment the segment’s growth. Early detection enables healthcare professionals to make effective clinical decisions. The growing demand for personalized therapeutics also potentiates the need for molecular diagnostics. Technological advancements lead to innovations in immunoassay techniques, such as ELISA, Western blot, immunohistochemistry, and flow cytometry.

The biomedical research segment is predicted to witness significant growth in the market over the forecast period. Biomedical research refers to investigating biological processes and cellular and molecular mechanisms of human diseases using scientific methods. Polyclonal antibodies play a vital role in assessing the disease progression, allowing researchers to develop targeted therapeutics. The growing proteomics and genomics research also fosters the segment’s growth.

Source Insights

The rabbit segment led the global market in 2024. Polyclonal antibodies extracted from rabbits usually possess a strong and diverse immune response. Rabbits are increasingly preferred as host species for a variety of applications, such as research, diagnostics, and clinical applications. Polyclonal antibodies from rabbits result in the extraction of high-affinity antibodies. Hence, they provide more extensive target recognition capabilities compared to other antibodies.

The mouse segment is anticipated to grow with the highest CAGR in the polyclonal antibodies market during the studied years. The increasing demand for a mouse as a preferred laboratory animal propels the segment’s growth. The extraction process of polyclonal antibodies from a mouse is generally easier than from rabbits. Mice have a strong immune system and are capable of generating a robust antibody response. Additionally, mice have greater genetic similarities to humans, eliminating the need for major modifications.

End-Use Insights

The hospitals & diagnostic centers segment registered its dominance over the global market in 2024. Polyclonal antibodies have widespread clinical applications, including disease diagnosis and treatment. The rising prevalence of infectious diseases and cancer necessitates that patients visit diagnostic laboratories, increasing the demand for immunodiagnostics. The growing number of antibody-based drug launches contributes to the segment’s growth. Hospitals & diagnostic centers have favorable infrastructure and suitable capital investments to adopt advanced diagnostics and therapeutics.

The pharmaceutical & biotechnology companies segment is projected to expand rapidly in the polyclonal antibodies market in the coming years. The segmental growth is attributed to the growing research and development activities, the presence of skilled professionals, and favorable infrastructure. The rising number of biopharma startups increases market competitiveness. This encourages companies to expand their product pipeline, potentiating the development of antibody-based drugs.

Top Companies in the Market

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Abcam plc.
• ProteoGeni
• Proteintech Group, Inc.
• Bio-Rad Laboratories Inc.
• BPS Bioscience, Inc.
• R&D Systems, Inc.
• Agilent Technologies, Inc.
• Atlas Antibodies
• Cusabio Technology LLC
• Rockland Immunochemicals, Inc.

Recent Breakthroughs in the Polyclonal Antibodies Market

• In October 2024, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) provided a grant to GigaGen, Inc. of $135.6 million over six years. The investment was provided to develop recombinant polyclonal antibody therapeutics targeting botulinum neurotoxins (BoNT).
• In August 2024, the U.S. FDA approved the Phase 1 clinical trial of GIGA-2339, a recombinant polyclonal antibody treatment for hepatitis B virus (HBV) infection, developed by GigaGen. The trial will test the safety and tolerability of GIGA-2339.

Browse More Insights of Towards Healthcare:

Anti-Inflammatory Drugs Market Regulatory Trends and Strategies by 2034

Anti-Obesity Drugs Market Size, Trends, Innovations and Growth Drivers

Monoclonal Antibodies in Veterinary Health Market Advancing Animal Health and Disease Management

Monoclonal Antibodies Therapeutics Market Drivers & Future Trends

Sterile Antimicrobial Gel Market Size to Extend $3.05 Bn by 2034

Direct Oral Anticoagulants (DOACs) Market to Boost $102.36 Bn by 2034

Complement C4 Antibody Market Size to Hit $68.48 Bn by 2034

Anti-Viral Nasal Spray Market Size and Developments

Antisense and RNAi Therapeutics Market to Soar USD 30.03 Bn by 2033

Antibody Drug Conjugate Market Size (USD 27.37 Bn) Report by 2033

Segments Covered in the Report

By Product

• Secondary Antibodies
• Primary Antibodies

By Application

• Diagnostics
• Biomedical Research

By Source

• Rabbit
• Mouse
• Goat
• Sheep
• Others
  

By End-Use

• Hospitals & Diagnostic Centers
• Pharmaceutical & Biotechnology Companies
• Academic & Research Center
  

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy 
  • Spain
  • Sweden 
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Access Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5388

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare